STOCK TITAN

Beta Bionics officer sells 775 shares at $16.22

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) Chief Commercial Officer Mark Hopman exercised options for 775 shares at $5.10 per share on November 16, 2026, acquiring 775 common shares. He sold 775 shares at $16.22 per share that day under a Rule 10b5-1 plan adopted on June 10, 2026. His reported option holdings were 20,950 shares after the exercise. The options vest in 48 equal monthly installments measured from September 14, 2023.

Insider Hopman Mark
Role Chief Commercial Officer
Sold 775 shs ($13K)
Approx. gross sale proceeds $13K
Approx. exercise cost $4K
Approx. pre-tax spread $9K
Share of Position Sold 1.4%
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F2 775 $0.00 $0.00
Exercise Common Stock 775 $5.10 $4K
Sale Common Stock F1 775 $16.22 $13K
Holdings After Transaction: Employee Stock Option (right to buy) — 20,950 options (Direct); Common Stock — 54,143 shares (Direct)
Holdings Before and After: Employee Stock Option (right to buy), 21,725 to 20,950 options (Direct); Common Stock, 54,143 to 54,143 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
  1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
  2. F2. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Options exercised 775 shares November 16, 2026
Option exercise price $5.10 per share November 16, 2026
Common shares acquired 775 shares November 16, 2026
Common shares sold 775 shares November 16, 2026
Sale price $16.22 per share November 16, 2026
Option holdings after exercise 20,950 shares Reported following the November 16, 2026 exercise
Rule 10b5-1 Plan regulatory
"shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
vesting financial
"shares subject to this option shall vest in 48 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBNX shares did Mark Hopman sell and at what price?

Mark Hopman sold 775 shares at $16.22 per share on November 16, 2026, pursuant to a Rule 10b5-1 plan adopted on June 10, 2026.

How many BBNX options did Mark Hopman exercise, and at what price?

He exercised options covering 775 shares at $5.10 per share on November 16, 2026, and acquired 775 common shares. His reported option holdings afterward were 20,950 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hopman Mark

(Last)(First)(Middle)
C/O BETA BIONICS, INC.
11 HUGHES

(Street)
IRVINE CALIFORNIA 92618

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M775A$5.154,918D
Common Stock11/16/2026S(1)775D$16.2254,143D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$5.111/16/2026M775 (2)09/13/2033Common Stock775$0.0020,950D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
2. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Remarks:
/s/ Thomas Sohn, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading